Grefberg N, Danielson B G, Nilsson P
Scand J Urol Nephrol. 1983;17(3):337-42. doi: 10.3109/00365598309182142.
The outcome of the first 50 patients started on Continuous Ambulatory Peritoneal Dialysis (CAPD) in one centre is reported. The total treatment time was 779 months. Ten patients died while on CAPD. Thirteen patients were transplanted, 4 of whom returned to CAPD after graft failure, 7 were transferred to other forms of dialysis and one to another centre. Twenty-three patients remained on the method. Good control of the symptoms and biochemical parameters of uremia was achieved. The patients were content with a high degree of well-being and freedom from dietary and fluid restrictions. The costs were found to be low. Peritonitis was a major complication, accounting for one death and four transfers to hemodialysis. The total incidence was one episode per every sixth patient month. CAPD represents an important contribution to the treatment of chronic renal failure. Nevertheless peritonitis remains a serious problem and the long-term metabolic effects of CAPD are unknown.
报告了在一个中心开始接受持续性非卧床腹膜透析（CAPD）治疗的首批50例患者的治疗结果。总治疗时间为779个月。10例患者在接受CAPD治疗期间死亡。13例患者接受了移植，其中4例在移植失败后又恢复了CAPD治疗，7例转为其他透析方式，1例转至另一中心。23例患者继续采用该方法治疗。尿毒症的症状和生化指标得到了良好控制。患者对高度的幸福感以及无需饮食和液体限制感到满意。发现成本较低。腹膜炎是主要并发症，导致1例死亡和4例转为血液透析。总发生率为每6个患者月发生1次。CAPD是对慢性肾衰竭治疗的一项重要贡献。然而，腹膜炎仍然是一个严重问题，且CAPD的长期代谢影响尚不清楚。
